Resources
THU, JUN 9, 2022 11:00 AM – 12:00 PM EDT Register >> Assessing clinical and functional status in Multiple Sclerosis (MS) using the Expanded Disability Status Scale (EDSS) is critical to inform treatment decisions and monitoring the progression of illness. Yet, EDSS scores are documented infrequently and inconsistently due to the time required to complete[…]
Pharmaceutical Executive Online Read the Full Article >> An estimated 64 million people suffer from heart failure (HF) globally. Americans have a 20% lifetime risk of developing HF. Although recent progress in the development of new treatments has led to a modest decrease in morbidity and mortality, mortality for heart failure patients remains unacceptably high[…]
Thu, May 26, 2022 11:00 AM – 12:00 PM EDT Register>> As the call for more diversity in clinical research grows, new approaches are needed to ensure patients of different genders, ethnicities, income brackets, and other under-represented populations are included in the evaluation of treatment access, effectiveness, and safety. Real-world data (RWD) can help with[…]
Thu, Apr 21, 2022 11:00 AM – 12:00 PM EDT Register>> There has been substantial recent progress in new heart failure (HF) treatments, yet there is still a large unmet need in the treatment of HF with preserved, mid-range, and reduced ejection fraction as well those with co-morbidities. Linked real-world data (RWD) can provide a[…]
Real-World Evidence Alliance Online Read the Full Article>> Washington, D.C. (April 5, 2022) – The RWE Alliance is pleased to announce the addition of five new members—ConcertAI, OM1, Syneos Health, Verana Health, and Verily—to continue to advance policies to support regulatory use of real-world evidence (RWE). The RWE Alliance is a policy and advocacy coalition of real-world data (RWD) and analytics organizations with[…]
